Stryker Co. (NYSE:SYK) Shares Acquired by First National Trust Co

First National Trust Co raised its holdings in shares of Stryker Co. (NYSE:SYK) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,187 shares of the medical technology company’s stock after purchasing an additional 820 shares during the period. First National Trust Co’s holdings in Stryker were worth $6,548,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in SYK. Atala Financial Inc acquired a new position in shares of Stryker in the 4th quarter valued at $53,000. LBP AM SA increased its position in shares of Stryker by 2.9% in the 4th quarter. LBP AM SA now owns 205,810 shares of the medical technology company’s stock valued at $74,102,000 after acquiring an additional 5,853 shares during the period. Impact Capital Partners LLC purchased a new stake in Stryker in the fourth quarter valued at $639,000. DecisionMap Wealth Management LLC purchased a new stake in Stryker in the fourth quarter valued at $280,000. Finally, HBK Sorce Advisory LLC boosted its holdings in Stryker by 16.8% in the fourth quarter. HBK Sorce Advisory LLC now owns 807 shares of the medical technology company’s stock valued at $291,000 after purchasing an additional 116 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SYK has been the topic of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $442.00 target price on shares of Stryker in a research note on Wednesday, January 29th. Barclays raised their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. The Goldman Sachs Group set a $422.00 target price on Stryker in a research report on Tuesday, March 4th. Stifel Nicolaus raised their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus target price of $421.90.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

NYSE:SYK opened at $363.79 on Friday. The company has a fifty day simple moving average of $382.87 and a two-hundred day simple moving average of $373.26. The company has a market cap of $138.81 billion, a price-to-earnings ratio of 46.88, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the business earned $3.46 earnings per share. As a group, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.